Active ingredient combination for the pharmacological therapy of nicotine dependence
OwnerKlaus Opitz, Joachim Moormann +1inventors
InventorsKlaus Opitz, Joachim Moormann, Hermann Mucke
Life of this patent
Estimating the term…
Abstract
The present invention relates to an active ingredient combination composed of at least one modulator of the cholinergic system with at least one substance blocking central opioid receptors for the pharmacological treatment of nicotine dependence.
Claims19
Active ingredient combination composed of at least one inhibitor of cholinesterase, which inhibitor also acts on dopaminergic nerve endings, with at least one substance modulating the opioid receptor system for the pharmacological therapy of nicotine dependence.
Active ingredient combination according to any of the preceding claims, characterized in that it is in the form of a pharmaceutical form where the single dose of galanthamine, its pharmacologically acceptable salts, addition compounds or derivatives to be administered is preferably in a range from 1-50 mg, or the single dose of deoxypeganine or its pharmacologically acceptable salts, addition compounds or derivatives to be administered is preferably in a range from 10-500 mg.
Active ingredient combination according to any of the preceding claims, characterized in that it is in the form of a pharmaceutical form where the single dose of naltrexone, its pharmacologically acceptable salts, addition compounds or derivatives to be administered is preferably in a range from 1 to 200 mg, or the single dose of cyclazocine or pentazocine, their pharmacologically acceptable salts or derivatives to be administered is preferably in a range from 5 to 100 mg.
Active ingredient combination according to any of the preceding claims, characterized in that it is in the form of a pharmaceutical form which has a depot effect.
Active ingredient combination according to any of the preceding claims, characterized in that it is in the form of a medicament to be administered orally.
Active ingredient combination according to any of the preceding claims, characterized in that it is in the form of a medicament to be administered parenterally.
Dependencies are inferred from the claim text.